105 related articles for article (PubMed ID: 16445969)
1. A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference.
Palmer C; Pratt J; Basu B; Earl H
Gynecol Oncol; 2006 Apr; 101(1):4-11. PubMed ID: 16445969
[TBL] [Abstract][Full Text] [Related]
2. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer.
Parker PA; Kudelka A; Basen-Engquist K; Kavanagh J; de Moor J; Cohen L
Gynecol Oncol; 2006 Mar; 100(3):495-500. PubMed ID: 16242759
[TBL] [Abstract][Full Text] [Related]
3. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
4. Nurse led telephone follow up in ovarian cancer: a psychosocial perspective.
Cox A; Bull E; Cockle-Hearne J; Knibb W; Potter C; Faithfull S
Eur J Oncol Nurs; 2008 Dec; 12(5):412-7. PubMed ID: 18845479
[TBL] [Abstract][Full Text] [Related]
5. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
Menczer J; Chetrit A; Sadetzki S; Golan A; Levy T
Gynecol Oncol; 2006 Oct; 103(1):137-40. PubMed ID: 16564077
[TBL] [Abstract][Full Text] [Related]
7. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
[TBL] [Abstract][Full Text] [Related]
8. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
9. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
10. Views of UK melanoma patients on routine follow-up care.
Dancey A; Rayatt S; Courthold J; Roberts J
Br J Plast Surg; 2005 Mar; 58(2):245-50. PubMed ID: 15710122
[TBL] [Abstract][Full Text] [Related]
11. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
[TBL] [Abstract][Full Text] [Related]
12. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Smyth JF; Gourley C; Walker G; MacKean MJ; Stevenson A; Williams AR; Nafussi AA; Rye T; Rye R; Stewart M; McCurdy J; Mano M; Reed N; McMahon T; Vasey P; Gabra H; Langdon SP
Clin Cancer Res; 2007 Jun; 13(12):3617-22. PubMed ID: 17575226
[TBL] [Abstract][Full Text] [Related]
14. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
[TBL] [Abstract][Full Text] [Related]
15. Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer.
Jordens CF; Morrell B; Harnett P; Hobbs K; Mason C; Kerridge IH
Soc Sci Med; 2010 Nov; 71(9):1548-56. PubMed ID: 20832155
[TBL] [Abstract][Full Text] [Related]
16. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
[TBL] [Abstract][Full Text] [Related]
17. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
Lewis MR; Euscher ED; Deavers MT; Silva EG; Malpica A
Gynecol Oncol; 2007 May; 105(2):395-8. PubMed ID: 17335881
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
19. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
Coleman RL; Gordon A; Barter J; Sun S; Rackoff W; Herzog TJ
Oncologist; 2007 Jan; 12(1):72-8. PubMed ID: 17227902
[TBL] [Abstract][Full Text] [Related]
20. Follow-up after treatment for breast cancer: one strategy fits all? An investigation of patient preferences using a discrete choice experiment.
Kimman ML; Dellaert BG; Boersma LJ; Lambin P; Dirksen CD
Acta Oncol; 2010 Apr; 49(3):328-37. PubMed ID: 20148645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
